After the demise of Dr.Hubertus van Dierendonck, Mr. Alec van Dierendonck assumed the role as the CEO of the company as his successor. Being the President of the corporation and regional manager of EGI Southeast Asia for the past years, he gained adequate experience to continue the legacy of his father. His vision is not only about maintaining the existing network but also expand and make Eurogenerics as one of the leading companies in the industry.
In the past decade, EGIP has registered almost 300 products with the Food and Administration (FDA), many of them are now well accepted in the market. The products are being distributed through a nationwide network that includes reputable marketing and distribution companies.
EGIP aims to become a leading pharmaceutical company specializing in the development of high-class pharmaceutical products tailor made towards the needs of its customers and markets. To achieve this, EGIP is
innovative and creative in product selection and development
excellent in maintaining the highest professional levels
pro-active in recognizing future trends within the industry
inspirational for its people who are the core of the company
loyal to its key of success: to provide quality medicine at affordable prices.
As worthy on upholding the highest professional levels, EGIP perceives the pharmaceutical industry within the context of an increasingly changing field of social and economic interactions. In this climate, the company realizes its future depends on the right decisions towards the opportunities based on the changing needs of the society and constantly being resourceful to promote outstanding product selections.
Services | |
Payment Methods |
Mauris ut cursus nunc. Morbi eleifend, ligula at consectetur vehicula